DVT Prevention: What Is Happening in the “Real World”?

Samuel Z. Goldhaber

doi:10.1055/s-2003-45414

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29: 023-032
DOI: 10.1055/s-2003-45414

DVT Prevention: What Is Happening in the “Real World”?

Samuel Z. Goldhaber

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Abstract

ABSTRACT

Pulmonary embolism (PE) and deep venous thrombosis (DVT) remain major problems in medicine that receive less attention from healthcare professionals and the public than either coronary artery disease or acute myocardial infarction. Furthermore, strategies proven to minimize the frequency of PE and DVT are not widely employed on a consistent and effective basis. The problem is widespread and affects patients in acute care hospitals, rehabilitation hospitals, and skilled nursing facilities, as well as high-risk individuals at home. Internists, general practitioners, and family doctors confront the greatest challenges in implementing appropriate prophylaxis. Models for effective change exist in cardiovascular and surgical practices where the imperative for prevention of further disease is insisted upon and ingrained in the culture of clinicians.

We will review the epidemiology of venous thromboembolism, strategies for the primary and secondary prevention of PE and DVT, “real world” use of prophylaxis, barriers to change that exist in the “real world,” and initiatives to improve day-to-day practice. We will conclude by posing 10 questions for future research on this topic.

KEYWORDS

Deep venous thrombosis - prophylaxis - venous thromboembolism - risk

Full Text

References

REFERENCES

1 Goldhaber S Z, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet . 1999; 353 1386-1389
2 McHugh K B, Visani L, DeRosa M, Covezzoli A, Rossi E, Goldhaber S Z. Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary Embolism Registry [ICOPER]). Am J Cardiol . 2002; 89 616-619
3 Nakamura M, Fujioka H, Yamada N. et al . Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol . 2001; 24 132-138
4 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton III J L. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med . 1999; 159 445-453
5 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton III J L. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med . 1998; 158 585-593
6 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'étude de la Thrombose de Bretagne Occidentale. Thromb Haemost . 2000; 83 657-660
7 Oger E, Bressollette L, Nonent M. et al . High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost . 2002; 88 592-597
8 Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost . 2003; 89 493-498
9 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med . 2000; 160 3415-3420
10 Tsai A W, Cushman M, Rosamond W D, Heckbert S R, Polak J F, Folsom A R. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med . 2002; 162 1182-1189
11 Goldhaber S Z, Grodstein F, Stampfer M J. et al . A prospective study of risk factors for pulmonary embolism in women. JAMA . 1997; 277 642-645
12 Joffe H V, Goldhaber S Z. Upper-extremity deep vein thrombosis. Circulation . 2002; 106 1874-1880
13 McGee D C, Gould M K. Preventing complications of central venous catheterization. N Engl J Med . 2003; 348 1123-1133
14 Chasan-Taber L, Stampfer M J. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med . 1998; 128 467-477
15 Jick H, Kaye J A, Vasilakis-Scaramozza C, Jick S S. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995; cohort and case-control analysis. BMJ . 2000; 321 1190-1195
16 Greer I A. Thrombosis in pregnancy: maternal and fetal issues. Lancet . 1999; 353 1258-1265
17 Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D. Postmenopausal hormone replacement therapy: scientific review. JAMA . 2002; 288 872-881
18 Hulley S, Furberg C, Barrett-Connor E. et al . Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA . 2002; 288 58-66
19 Rossouw J E, Anderson G L, Prentice R L. et al . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA . 2002; 288 321-333
20 Joffe H V, Goldhaber S Z. Laboratory thrombophilias and venous thromboembolism. Vasc Med . 2002; 7 93-102
21 Lapostolle F, Surget V, Borron S W. et al . Severe pulmonary embolism associated with air travel. N Engl J Med . 2001; 345 779-783
22 National Experts' Consensus Panels for Clinical Excellence in Thrombosis Management. Prophylaxis of venous thromboembolism (VTE) in the hospitalized medical patient. Hospital Medicine Consensus Reports. May 1, 2003: 1-18
23 Comerota A J, Chouhan V, Harada R N. et al . The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg . 1997; 226 306-313
24 Samama M M, Cohen A T, Darmon J Y. et al . A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med . 1999; 341 793-800
25 Leizorovicz A, Cohen A T, Turpie A G, Olsson C G, Vaitkus P T, Goldhaber S Z, for the PREVENT Medical Thromboprophylaxis Study Group. A randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ISTH Abstract OC396. Presented on July 18, 2003 in Birmingham, England
26 Gallus A S, Coghlan D W. Heparin pentasaccharide. Curr Opin Hematol . 2002; 9 422-429
27 Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet . 2002; 359 1710-1711
28 Bergqvist D, Agnelli G, Cohen A T. et al . Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med . 2002; 346 975-980
29 Eikelboom J W, Quinlan D J, Douketis J D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet . 2001; 358 9-15
30 Mismetti P, Laporte-Simitsidis S, Tardy B. et al . Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost . 2000; 83 14-19
31 Schulman S, Rhedin A S, Lindmarker P. et al . A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med . 1995; 332 1661-1665
32 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Fallon W M, Melton III J L. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med . 2000; 160 761-768
33 Ridker P M, Goldhaber S Z, Danielson E. et al . Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med . 2003; 348 1425-1434
34 Kakkar V V, Corrigan T P, Fossard D P. et al . Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an International Multicentre Trial. Lancet . 1975; 2 45-51
35 Collins R, Scrimgeour A, Yusuf S. et al . Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med . 1988; 318 1162-1173
36 Keane M G, Ingenito E P, Goldhaber S Z. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest . 1994; 106 13-14
37 Hirsch D R, Ingenito E P, Goldhaber S Z. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA . 1995; 274 335-337
38 Goldhaber S Z. Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest . 1998; 113 5-7
39 Goldhaber S Z, Dunn K, MacDougall R C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest . 2000; 118 1680-1684
40 Geerts W H, Heit J A, Clagett G P. et al . Prevention of venous thromboembolism. Chest . 2001; 119(1 suppl) 132S-175S
41 Grasso-Correnti N, Goldszer R C, Goldhaber S Z. The critical pathways of an anticoagulation service. Critical Pathways in Cardiology . 2003; 2 41-45
42 Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA . 2000; 283 2816-2821